Table 1 Basic information on the surgical treatment results of MRONJ patients caused by anti-resorptive drugs and anti-resorptive drugs plus anti-angiogenic drugs
Variable | Anti-resorptivedrug group (n = 74) | Anti-resorptive drug + anti-angiogenic drug group (n = 31) | P |
|---|---|---|---|
Gender | |||
 Male | 28 (37.84) | 21 (67.74) | 0.006‡ |
 Female | 46 (62.16) | 10 (32.26) | |
Average age ± SD (year) | 65.18 ± 10.34 | 61.32 ± 5.92 | 0.061* |
Duration of anti-resorptive drugs in months ± SD | 37.09 ± 28.91 | 26.61 ± 15.25 | 0.005* |
Anti-angiogenic medications | |||
 Suntinib | NA | 9 (29.03) | NA |
 Bevacizumab | 10 (32.26) | ||
 Anlotinib | 5 (16.13) | ||
 others | 7 (22.58) | ||
Underlying disease | |||
 Osteoporosis | 11 (14.86) | 0 (0.00) | NA |
 Breast cancer | 25 (33.78) | 4 (12.90) | |
 Lung cancer | 15 (20.27) | 17 (54.84) | |
 Kidney cancer | 0 (0.00) | 8 (25.81) | |
 Prostate cancer | 15 (20.27) | 0 (0.00) | |
 Multiple myeloma | 7 (9.46) | 0 (0.00) | |
 Others | 1 (1.35) | 2 (6.45) | |
MRONJ location | |||
 Maxilla | 24 (32.43) | 11 (35.48) | 0.466‡ |
 Mandible | 50 (67.57) | 20 (64.52) | |
Clinical symptom | |||
 Jaw exposure | 31 (41.89) | 22(70.97) | 0.010 |
 Skin or mucosa fistula | 43 (58.11) | 9 (29.03) | |
MRONJ stage | |||
 1 | 16 (21.62) | 2 (6.45) | 0.031‡ |
 2 | 43 (58.11) | 16 (51.61) | |
 3 | 15 (20.27) | 13 (41.94) | |
Surgical methods | |||
 Marginal osteotomy | 64 (86.49) | 24 (77.42) | 0.259‡ |
 Segment osteotomy | 10 (13.51) | 7 (22.58) | |
Treatment results | |||
 Healed | 52 (70.27) | 12 (38.71) | 0.004‡ |
 Non-healing | 22 (29.73) | 19 (61.29) | |